Collectively, our findings establish hepatocyte Mettl3 deficiency as a pivotal driver of PSC pathogenesis and highlight the therapeutic potential of targeting the m6A epitranscriptome in cholestatic liver diseases. This evidence concerns the gene METTL3 and Cholestatic liver disease.